Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
5th May 20157:01 amRNSIssue of Equity
28th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20157:00 amRNSNotice of Results
23rd Mar 20157:00 amRNSDrug discovery partnership
23rd Mar 20157:00 amRNSIssue of Equity
12th Feb 20157:00 amRNSSale of Optim Trade and Assets
9th Feb 20157:00 amRNSAffimer Development Contract with Protatonce
23rd Jan 20152:31 pmRNSResult of AGM
23rd Jan 20157:00 amRNSTrading Statement
16th Jan 20157:00 amRNSCommercial Partnership in the Agri-bio Market
6th Jan 20157:00 amRNSIssue of Equity
22nd Dec 20147:00 amRNSPosting of Annual Report & Accounts and AGM Notice
16th Oct 20147:00 amRNSFinal Results
30th Sep 20147:00 amRNSAffimer On-line Catalogue Launch
29th Sep 20147:00 amRNSInvestor Briefing
22nd Sep 20147:00 amRNSAppointment of a Senior Executive
4th Aug 20147:00 amRNSNew OPTIM Software and Hardware
1st Aug 20147:00 amRNSPre Close Trading Update
15th Jul 20147:00 amRNSMajor Japanese Distributor Signed
13th Jun 201411:04 amRNSHolding(s) in Company
2nd Jun 20141:04 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSAvacta Secures Funding Award
30th May 20144:37 pmRNSHolding(s) in Company
30th May 20142:52 pmRNSHolding(s) in Company
29th May 20144:21 pmRNSHolding(s) in Company
28th May 20147:00 amRNSAvacta Life Sciences Exhibits Affimers at PEGS
23rd May 201412:53 pmRNSResult of General Meeting
21st May 20145:36 pmRNSHolding(s) in Company
14th May 20147:00 amRNSIssue of Equity
9th May 20144:19 pmRNSDirector's dealing
9th May 20147:00 amRNSAvacta Announce Collaboration with UbiQ Bio BV
7th May 20147:00 amRNSConditional Placing
23rd Apr 20147:00 amRNSInterim Results
14th Apr 20147:00 amRNSAvacta Launch Pancreatitis Test for Dogs
20th Mar 20147:00 amRNSAffimers : Technical and Commercial Update
11th Mar 20147:00 amRNSNotice of Interim Results
24th Feb 20147:00 amRNSDirectors Dealings
5th Feb 20147:00 amRNSNew Board Appointment
4th Feb 20149:29 amRNSHolding(s) in Company
3rd Feb 20147:00 amRNSAvacta Initiates Collaboration with University
28th Jan 20147:00 amRNSAvacta Life Sciences Launches Affimers Web Site
24th Jan 20142:57 pmRNSResult of AGM
24th Jan 20147:00 amRNSAGM Statement
20th Jan 20147:00 amRNSIssue of Equity
13th Jan 20147:00 amRNSInvestor teach-in
23rd Dec 20132:59 pmRNSNotice of AGM and Report and Accounts
23rd Dec 20137:00 amRNSBoard Appointment
27th Nov 201310:01 amRNSNew Canine Lymphoma Blood Test Launched
1st Nov 20137:00 amRNSIssue of Equity
24th Oct 20137:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.